BSW Wealth Partners Invests $385,000 in Regeneron Pharmaceuticals, Inc. $REGN

BSW Wealth Partners acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 684 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the last quarter. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $628,151,000. Acadian Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Invesco Ltd. increased its position in shares of Regeneron Pharmaceuticals by 26.5% during the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on REGN shares. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Truist Financial began coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $798.00 price objective on the stock. Guggenheim raised their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $779.45.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.2%

Shares of Regeneron Pharmaceuticals stock opened at $784.97 on Friday. The stock has a market capitalization of $82.50 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 2.25 and a beta of 0.37. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $792.77. The stock has a 50 day moving average price of $703.50 and a two-hundred day moving average price of $609.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period last year, the business earned $12.46 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.